Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
There are two ways to transport FFAs into
2024-08-09

There are two ways to transport FFAs into cells. First by passive diffusion. Second as the putative long-chain fatty LY3009120 receptor transporters are proposed, CD36 the plasma membrane-associated fatty acid-binding protein (FABPpm) and fatty acid transport proteins (FATP) [11], where CD36 is res
-
In recent years there have been further significant developm
2024-08-08

In recent years, there have been further significant developments that enhance an understanding of the role of adenosine in nociception. Thus, novel methods of recruiting adenosine A1Rs have been developed, and the role of adenosine A2A- and A3Rs in nociception has been further elaborated. Furthermo
-
sVRPs were more sensitive to ABT than
2024-08-08

sVRPs were more sensitive to ABT-702 than MSRs. This result agrees with previous reports that the activation of A1 receptors more potently inhibits sVRPs than MSRs (Nakamura et al., 1997, Otsuguro et al., 2009). Importantly, sVRPs are thought to reflex C-fiber-evoked nociceptive transmission. Nocice
-
The earliest appearance of tumors occurred at
2024-08-08

The earliest appearance of tumors occurred at 12 months and the latest at 24 months, with an average onset at 18 months (Fig. 1B). This would be roughly equivalent to cancer presenting in a patient between 60 and 70 years of age. In transgenic animals, autotaxin OSI-930 was relatively increased in
-
In response to DSB the
2024-08-08

In response to DSB, the lesion recognition factor Mre11-Rad50-Nbs1 (MRN) complex helps the recruitment of ATM to the damage site and its activation by phosphorylation [29]. However, whether UV-damage recognition factors directly influence ATR and ATM recruitment and their phosphorylation is not clea
-
The class C receptors also share a common
2024-08-08

The class C receptors also share a common agonist-binding mode. In all cases, an agonist induces VFT closure by forming intermolecular bonds with surface residues in both the LB1 and LB2 domains (Geng et al., 2013, Geng et al., 2016, Kunishima et al., 2000, Muto et al., 2007, Nuemket et al., 2017, T
-
GABAB receptor is associated with brain and
2024-08-08

GABAB receptor is associated with Alverine Citrate and behavioral diseases, including epilepsy, spasticity, anxiety and neuropathic pain (Bettler et al., 2004, Bowery et al., 2002, Froestl, 2010). Baclofen, a clinical drug and selective GABAB receptor agonist, is used to treat muscle spasticity in
-
Numerous investigators have shown that RACK has several impo
2024-08-08

Numerous investigators have shown that RACK1 has several important, possibly related, roles in mRNA splicing and in translation. RACK1 interacts directly with specific components of the 40S ribosomal subunit (specifically, the 18S rRNA and ribosomal proteins rpS16e, rpS17e, and rpS3e [new names: uS9
-
AMPK is a cellular energy sensor that is phosphorylated
2024-08-08

AMPK is a cellular energy sensor that is phosphorylated in response to high intracellular ADP levels to increase GLUT4 translocation into the cell, and subsequently, increase intracellular glucose levels to provide substrate to replenish ATP levels [25]. In metabolic syndrome, sequestration of plasm
-
br Acknowledgments and Disclosures br Alzheimer s
2024-08-08

Acknowledgments and Disclosures Alzheimer's disease as a synaptic pathology Alzheimer's disease (AD) is a chronic neurodegenerative Tamoxifen disorder and the most common cause of dementia in the elderly. Progressive depositions of amyloid plaques and neurofibrillary tangles together with deg
-
Second the phosphorylation events e g Thr
2024-08-07

Second, the phosphorylation events (e.g., α-Thr172 and β-Ser108) needed for AMPK activation by small molecules binding at the ADaM or other sites remains unclear. Within the β-GBD, phosphorylation of β1-Ser108 was shown to be required for the activation by small molecules binding in the ADaM site, s
-
br Materials and methods br Results
2024-08-07

Materials and methods Results Discussion We have in this study used semi-nested degenerative PCR to identify the lipoxygenases expressed in the lung tissue from M. fascicularis and report on the identification of 5- and 12/15-LO transcripts from this tissue. Although we did not find transcr
-
First investigation of numerous membered ether linked macroc
2024-08-07

First, investigation of numerous 12-14-membered ether-linked macrocycles revealed that smaller motifs were most lipophilic efficient. Compound (3) (12-membered macrocycle) exhibited good cellular potencies (ALK IC50 = 1.0 nM; ALK-L1196 M IC50 = 20 nM) and the highest LipE (4.4) with picomolar bindin
-
The disease stimulatory effects of hyperadiponectinemia in p
2024-08-07

The disease-stimulatory effects of hyperadiponectinemia in patients contradict a previous view based on studies of preclinical models showing that APN might be beneficial for AD [8]. Indeed, despite the action of APN as a risk factor in patients with AD, APN is protective against oxidative stress-in
-
br Methods br Results From a study population
2024-08-07

Methods Results From a study population of 7069 patients, a total of 149 falls were reported during the study ALW-II-41-27 for an incidence rate (IR) of 5.2 falls per 1000 patient-days (PD), 95% confidence interval (CI) 4.4/1000 PD–6.1/1000 PD. The incidence rate ratio (IRR) for patients in t
15983 records 118/1066 page Previous Next First page 上5页 116117118119120 下5页 Last page